Citations

Citations to this article as recorded by  

• Impact of two COVID-19 lockdowns on HbA1c levels in patients with type 2 diabetes and associations with patient characteristics: a multicentre, observational cohort study over three years
  Ingmar Schäfer, Daniel Tajdar, Laura Walther, Lasse Bittner, Dagmar Lühmann, Martin Scherer
  Frontiers in Public Health.2024;[Epub]     CrossRef
• Influence of the COVID-19 pandemic on the achievement of guideline targets for HbA1c, blood pressure, and LDL cholesterol in people with diabetes in Japan
  Shingo Kuwajima, Takahito Itoh, Tatsuya Sato, Shoya Ino, Satoru Shibata, Kouhei Ohno, Hiroyuki Hotta, Tomoaki Matsumoto, Hitoshi Ooiwa, Hirofumi Kubo, Takayuki Miki
  Diabetology International.2024; 15(3): 507.     CrossRef
• Socioeconomic status and the effect of prolonged pandemic confinement on anthropometric and glycaemic outcomes in adults with type 2 diabetes mellitus
  Chandana Wijeweera, Ummul Muhfaza, Reginald V. Lord, Peter Petocz, Juliana Chen, Veronica Preda
  Primary Care Diabetes.2024; 18(3): 308.     CrossRef
• Physical and Mental Health Characteristics of Hospitalized COVID-19 Patients with and without Type 2 Diabetes Mellitus in Turkey
  Abdulbari Bener, Murat Atmaca, Abdulla O. A. A. Al-Hamaq, Antonio Ventriglio
  Brain Sciences.2024; 14(4): 377.     CrossRef
• The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
  Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, Dimitrios Patoulias, Paschalis Karakasis, Sophia Alexiou, Athanasios Samaras, Georgios Zormpas, George Stavropoulos, Dimitrios Tsalikakis, George Kassimis, Christodoulos Papadopoulos, Niko
  Journal of Clinical Medicine.2024; 13(18): 5408.     CrossRef
• Self-Care of Adults with Type 2 Diabetes During the COVID-19 Pandemic: A Qualitative Interpretive Description Study
  Michela Luciani, Camilla Bigoni, Marta Canesi, Matteo Masotto, Diletta Fabrizi, Stefania Di Mauro, Davide Ausili
  Clinical Nursing Research.2023; 32(1): 73.     CrossRef
• Changes in body weight and glycemic control in association with COVID-19 Shutdown among 23,000 adults with type 2 diabetes
  Emily Panza, Kevin E. Kip, Kripa Venkatakrishnan, Oscar C. Marroquin, Rena R. Wing
  Acta Diabetologica.2023; 60(6): 787.     CrossRef
• The Impact of a Lockdown for the COVID-19 Pandemic on Seasonal HbA1c Variation in Patients with Type 2 Diabetes
  Yu-Cheng Cheng, Yu-Hsuan Li, Hsiu-Chen Liu, Chiann-Yi Hsu, Wan-Jen Chang, I-Te Lee, Chin-Li Lu
  Life.2023; 13(3): 763.     CrossRef
• Changes in the mean incidence and variance of orthopedic diseases before and during the COVID-19 pandemic in Korea: a retrospective study
  Joo-Hee Kim, Mi Jung Kwon, Hyo Geun Choi, Sang Jun Lee, Sangwon Hwang, Jaemin Lee, San-Hui Lee, Jung Woo Lee
  BMC Musculoskeletal Disorders.2023;[Epub]     CrossRef
• Gender differences-based bioinformatics analysis to identify hub genes and key pathways in type 2 diabetes
  Md Sojib Hossain, Subrina Islam Rupa, Md Sumon Sarkar, Md Al Amin, Mst Tania Khatun, Md Shamim, Md Zahidul Islam
  Informatics in Medicine Unlocked.2023; 40: 101302.     CrossRef
• Retrospective Study on the Impact of COVID-19 Lockdown on Patients with Type 2 Diabetes in Northern Taiwan
  Hsuan Huang, Hsiao-Ling Su, Chih-Hsung Huang, Yi-Hsin Lin
  Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2539.     CrossRef
• Understanding impacts of COVID-19 restrictions on glycemic control for patients with diabetes in Japan
  Kiyoko Uno-Eder, Noriko Satoh-Asahara, Manabu Hibiya, Kenji Uno, Takuya Uchino, Koji Morita, Toshio Ishikawa, Tetsuji Kaneko, Hajime Yamakage, Yuki Kitaoka, Tomohiro Sawa, Kazuhisa Tsukamoto, Tamio Teramoto
  Journal of Diabetes & Metabolic Disorders.2023; 22(2): 1695.     CrossRef
• Impacts of the COVID-19 pandemic on unmet social needs, self-care, and outcomes among people with diabetes and poor glycemic control
  Minal R. Patel, Guanghao Zhang, Cindy Leung, Peter X.K. Song, Michele Heisler, Hae Mi Choe, Roshanak Mehdipanah, Xu Shi, Kenneth Resnicow, Geila Rajaee, John D. Piette
  Primary Care Diabetes.2022; 16(1): 57.     CrossRef
• Impact of the COVID-19 Pandemic on Glycemic Control and Blood Pressure Control in Patients with Diabetes in Japan
  Keisuke Endo, Takayuki Miki, Takahito Itoh, Hirofumi Kubo, Ryosuke Ito, Kouhei Ohno, Hiroyuki Hotta, Nobuo Kato, Tomoaki Matsumoto, Aya Kitamura, Mai Tamayama, Takako Wataya, Ayaka Yamaya, Rei Ishikawa, Hitoshi Ooiwa
  Internal Medicine.2022; 61(1): 37.     CrossRef
• The Effects of COVID-19 Lockdown on Glycaemic Control and Lipid Profile in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
  Omorogieva Ojo, Xiao-Hua Wang, Osarhumwese Osaretin Ojo, Edith Orjih, Nivedita Pavithran, Amanda Rodrigues Amorim Adegboye, Qian-Qian Feng, Paul McCrone
  International Journal of Environmental Research and Public Health.2022; 19(3): 1095.     CrossRef
• Lifestyles Under Lockdown: A Scoping Review of International Studies on Type 2 Diabetes Self-Management Behaviors During COVID-19
  Caroline Cummings, Kagnica Seng, Ryan Tweet, Julie Wagner
  Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
• Substitution of telemedicine for clinic visit during the COVID‐19 pandemic of 2020: Comparison of telemedicine and clinic visit
  Yukiko Onishi, Rieko Ichihashi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Toshiko Kobori, Tetsuya Kubota, Masahiko Iwamoto, Shoko Hamano, Masato Kasuga
  Journal of Diabetes Investigation.2022; 13(9): 1617.     CrossRef
• The impact of the COVID-19 pandemic on the management of patients with chronic diseases in Primary Health Care
  Panagiotis Stachteas, Manolis Symvoulakis, Apostolos Tsapas, Emmanouil Smyrnakis
  Population Medicine.2022; 4(August): 1.     CrossRef
• Effects of COVID-19 Pandemic and Lockdown on Monitoring and Treatment Balance of Finnish Coronary Heart Disease and Type 2 Diabetes Patients
  Piia Lavikainen, Marja-Leena Lamidi, Teppo Repo, Laura Inglin, Janne Martikainen, Tiina Laatikainen
  Clinical Epidemiology.2022; Volume 14: 1363.     CrossRef
• Impact of Social Distancing Due to Coronavirus Disease 2019 on the Changes in Glycosylated Hemoglobin Level in People with Type 2 Diabetes Mellitus (Diabetes Metab J 2021;45:109-14)
  Junghyun Noh
  Diabetes & Metabolism Journal.2021; 45(2): 275.     CrossRef
• Impact of Social Distancing Due to Coronavirus Disease 2019 on the Changes in Glycosylated Hemoglobin Level in People with Type 2 Diabetes Mellitus (Diabetes Metab J 2021;45:109-14)
  Sung-Don Park, Sung-Woo Kim, Jun Sung Moon, Jae-Han Jeon, Mi Kyung Kim, Keun-Gyu Park
  Diabetes & Metabolism Journal.2021; 45(2): 279.     CrossRef
• Glucose control in diabetes during home confinement for the first pandemic wave of COVID-19: a meta-analysis of observational studies
  Giovanni Antonio Silverii, Chiara Delli Poggi, Ilaria Dicembrini, Matteo Monami, Edoardo Mannucci
  Acta Diabetologica.2021; 58(12): 1603.     CrossRef
• The impact of COVID-19 pandemic on glycemic control in patients with diabetes mellitus in Turkey: a multi-center study from Kocaeli
  Alev Selek, Emre Gezer, Eda Altun, Mehmet Sözen, Ömercan Topaloğlu, Damla Köksalan, Halil Demirkan, Dilek Karakaya, Berrin Cetinarslan, Zeynep Cantürk, Dilek Taymez
  Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1461.     CrossRef
• Effects of Social Distancing on Diabetes Management in Older Adults during COVID-19 Pandemic
  Soo Myoung Shin, Tae Jung Oh, Sung Hee Choi, Hak Chul Jang
  Diabetes & Metabolism Journal.2021; 45(5): 765.     CrossRef
• Year-Long Trend in Glycated Hemoglobin Levels in Patients with Type 2 Diabetes during the COVID-19 Pandemic
  Jonghwa Jin, Seong Wook Lee, Won-Ki Lee, Jae-Han Jeon, Jung-Guk Kim, In-Kyu Lee, Yeon-Kyung Choi, Keun-Gyu Park
  Endocrinology and Metabolism.2021; 36(5): 1142.     CrossRef

Citations

Citations to this article as recorded by  

• Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
  Carmen Tisch, Eleni Xourgia, Aristomenis Exadaktylos, Mairi Ziaka
  Endocrine.2024; 85(2): 660.     CrossRef
• Insulin and Metformin Administration: Unravelling the Multifaceted Association with Mortality across Various Clinical Settings Considering Type 2 Diabetes Mellitus and COVID-19
  Łukasz Lewandowski, Agnieszka Bronowicka-Szydełko, Maciej Rabczyński, Dorota Bednarska-Chabowska, Joanna Adamiec-Mroczek, Adrian Doroszko, Małgorzata Trocha, Krzysztof Kujawa, Agnieszka Matera-Witkiewicz, Edwin Kuźnik, Paweł Lubieniecki, Marcin Madziarski
  Biomedicines.2024; 12(3): 605.     CrossRef
• Prognostic Value of Hyperglycemia and Insulin Resistance Among Patients with Confirmed COVID-19 Infections at Admission to the Alexandria Fever Hospital, Egypt
  Fathy Z. Alsewy, Magdy H. Megallaa, Salma A. Imbaby, Huda M. Zidan, Heba S. Kassab, Mai H. Badrah
  Metabolic Syndrome and Related Disorders.2024; 22(7): 551.     CrossRef
• The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
  Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, Jian-Bo Zhou, Chao Zhang
  Therapeutic Innovation & Regulatory Science.2024; 58(4): 773.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• The therapeutic potential of the use of gliclazide MV in combination with COVID-19 and type 2 diabetes mellitus
  D. V. Belikina, T. A. Nekrasova, L. G. Strongin, E. M. Durygina, M. Yu. Rodina
  FOCUS. Endocrinology.2024; 5(1): 20.     CrossRef
• Research status and hotspots in the field of endoplasmic reticulum stress and liver disease: A bibliometric study
  Ruiyu Wang, Shu Huang, Ping Wang, Xiaowei Tang, Huan Xu, Wei Zhang, Lei Shi, Xiaolin Zhong, Muhan Lü, Xian Zhou, Xiaomin Shi
  Medicine.2024; 103(22): e38450.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2024; 11: 729.     CrossRef
• Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
  Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
  Diabetes Research and Clinical Practice.2023; 195: 110205.     CrossRef
• Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
  Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
  Diabetologia.2023; 66(8): 1395.     CrossRef
• Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
  A. V. Alieva, A. A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Z. Khalilova, V. A. Talenova, N. U. Alimova, M. D. Aripova, A. S. Sadikova
  Obesity and metabolism.2023; 20(2): 92.     CrossRef
• Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
  Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
  Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
• Epidemiological features and consequences of COVID‐19 in patients with and without gastrointestinal symptoms in southwestern Iran. A retrospective observational study
  Habibollah Azarbakhsh, Leila Moftakhar, Aliasghar Valipour, Alireza Mirahmadizadeh, Hekmat Allah Moradi, Elahe Piraee
  Health Science Reports.2023;[Epub]     CrossRef
• The Impact of Long-Term Conditions and Comorbidity Patterns on COVID-19 Infection and Hospitalisation: A Cohort Study
  Yun-Ting Huang, Andrew Steptoe, Riyaz S. Patel, Esme Fuller Thomson, Dorina Cadar
  Gerontology.2023; 69(10): 1200.     CrossRef
• Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
  Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
  Archives of Medical Research.2022; 53(2): 186.     CrossRef
• Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
  Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
  Diabetes & Metabolism.2022; 48(1): 101307.     CrossRef
• Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
  Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
  Primary Care Diabetes.2022; 16(1): 162.     CrossRef
• Prevalence and impact of diabetes in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
  Sian A. Bradley, Maciej Banach, Negman Alvarado, Ivica Smokovski, Sonu M. M. Bhaskar
  Journal of Diabetes.2022; 14(2): 144.     CrossRef
• Interplay between Inflammaging, Frailty and Nutrition in Covid-19: Preventive and Adjuvant Treatment Perspectives
  A. Padilha de Lima, M. Macedo Rogero, T. Araujo Viel, H.M. Garay-Malpartida, I. Aprahamian, Sandra Maria Lima Ribeiro
  The Journal of nutrition, health and aging.2022; 26(1): 67.     CrossRef
• Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study
  Mi Seon Lee, Rosie Lee, Cheol Woo Ko, Jung Eun Moon
  Journal of Yeungnam Medical Science.2022; 39(1): 46.     CrossRef
• Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network
  Qian Gao, Wenjun Zhang, Tingting Li, Guojun Yang, Wei Zhu, Naijun Chen, Huawei Jin
  Scientific Reports.2022;[Epub]     CrossRef
• Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation
  Afnan Alshnbari, Iskandar Idris
  Current Medical Research and Opinion.2022; 38(3): 357.     CrossRef
• Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  Li-Min Zhao, Xie-Hui Chen, Mei Qiu
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• COVID-19 and Diabetes
  Awadhesh Kumar Singh, Kamlesh Khunti
  Annual Review of Medicine.2022; 73(1): 129.     CrossRef
• The enzymes in COVID-19: A review
  Maria Helena Menezes Estevam Alves, Layla Carvalho Mahnke, Tifany Cerqueira Macedo, Thais Ketinly dos Santos Silva, Luiz Bezerra Carvalho Junior
  Biochimie.2022; 197: 38.     CrossRef
• IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW
  Adnan A. Zainal, Marwan M. Merkhan
  Military Medical Science Letters.2022; 91(2): 140.     CrossRef
• Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis
  Adithan Ganesh, Michael D. Randall
  British Journal of Clinical Pharmacology.2022; 88(6): 2642.     CrossRef
• Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin
  Clifford J. Bailey, Mike Gwilt
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
  Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
  Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
• Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
  Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
  Metabolism.2022; 131: 155196.     CrossRef
• Glucose-Lowering Agents and COVID-19
  Ah Reum Khang
  The Journal of Korean Diabetes.2022; 23(1): 1.     CrossRef
• Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis
  Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
  Endocrinology, Diabetes & Metabolism.2022;[Epub]     CrossRef
• The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
  Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
  Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
  Journal of the American Heart Association.2022;[Epub]     CrossRef
• Diabetes and SARS-CoV-2–Is There a Mutual Connection?
  Anna P. Jedrzejak, Edyta K. Urbaniak, Jadwiga A. Wasko, Natalia Ziojla, Malgorzata Borowiak
  Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
• The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
  Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
  F1000Research.2022; 11: 729.     CrossRef
• Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?
  Marzieh Rohani-Rasaf, Kosar Mirjalili, Akram Vatannejad, Maryam Teimouri, Xiao-Feng Yang
  PLOS ONE.2022; 17(8): e0272000.     CrossRef
• Early glycaemic variability increases 28-day mortality and prolongs intensive care unit stay in critically ill patients with pneumonia
  Seong Ho Kim, Ji Young Kim, Eun Song Kim, Il Rae Park, Eun Yeong Ha, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
  Annals of Medicine.2022; 54(1): 2724.     CrossRef
• Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
  Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
  World Journal of Virology.2022; 11(6): 399.     CrossRef
• Prevalencia de secuelas en pacientes con diabetes mellitus tipo 2 sobrevivientes al COVID-19
  Gianela M. Cancino-Castillo, Miguel A. Tresierra-Ayala, Jorge L. Campos-Reyna, Jaime Rosales-Rimache
  REVISTA MÉDICA VALLEJIANA/ Vallejian Medical Journal.2022; 11(2): 48.     CrossRef
• Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq
  Hussein Nafakhi, Mohammed Alareedh, Karrar Al-Buthabhak, Foaad Shaghee, Ahmed Nafakhi, Samet Kasim
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 33.     CrossRef
• Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
  Awadhesh Kumar Singh, Ritu Singh, Banshi Saboo, Anoop Misra
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 159.     CrossRef
• COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis
  Mark Thomaz Ugliara Barone, Belinda Ngongo, Simone Bega Harnik, Lucas Xavier de Oliveira, Dániel Végh, Patrícia Vieira de Luca, Hermelinda Cordeiro Pedrosa, Franco Giraudo, Roque Cardona-Hernandez, Nayanjeet Chaudhury, Luiz Menna-Barreto
  Diabetes Research and Clinical Practice.2021; 171: 108587.     CrossRef
• A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
  Chia Siang Kow, Syed Shahzad Hasan
  Therapies.2021; 76(4): 361.     CrossRef
• Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
  B. M. Bonora, A. Avogaro, G. P. Fadini
  Journal of Endocrinological Investigation.2021; 44(7): 1379.     CrossRef
• Prognostic bioindicators in severe COVID-19 patients
  L. Bergantini, E. Bargagli, M. d'Alessandro, R.M. Refini, P. Cameli, L. Galasso, C. Scapellato, F. Montagnani, S. Scolletta, F. Franchi, S. Valente, D. Bennett, G. Sebastiani, B. Frediani, F. Dotta
  Cytokine.2021; 141: 155455.     CrossRef
• Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients
  Leila Moftakhar, Parisa Moftakhar, Elahe Piraee, Haleh Ghaem, Aliasghar Valipour, Habibollah Azarbakhsh
  International Journal of Diabetes in Developing Countries.2021; 41(3): 383.     CrossRef
• DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
  André J. Scheen
  Diabetes & Metabolism.2021; 47(2): 101213.     CrossRef
• Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
  Ronan Roussel, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, Leila Ait Bachir, Ingrid Allix, Deborah Ancelle, Sara Barraud, Lyse Bordier, Aurélie Carlier, Nicolas Chevalier, Christine Coffin‐Boutreux, Emmanuel Cosson, Anne Dorange, O
  Diabetes, Obesity and Metabolism.2021; 23(5): 1162.     CrossRef
• Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis
  Rimesh Pal, Mainak Banerjee, Soham Mukherjee, Ranjitpal Singh Bhogal, Amanpreet Kaur, Sanjay K. Bhadada
  Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub]     CrossRef
• Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
  Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, Giovanni Corrao, Franz H. Messerli
  Journal of Hypertension.2021; 39(4): 784.     CrossRef
• Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis
  Zeinab Abdelrahman, Qian Liu, Shanmei Jiang, Mengyuan Li, Qingrong Sun, Yue Zhang, Xiaosheng Wang
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
  Timotius Ivan Hariyanto, Andree Kurniawan
  Journal of Diabetes & Metabolic Disorders.2021; 20(1): 543.     CrossRef
• Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis
  Halla Kaminska, Lukasz Szarpak, Dariusz Kosior, Wojciech Wieczorek, Agnieszka Szarpak, Mahdi Al-Jeabory, Wladyslaw Gawel, Aleksandra Gasecka, Milosz J. Jaguszewski, Przemyslawa Jarosz-Chobot
  Acta Diabetologica.2021; 58(8): 1101.     CrossRef
• Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression
  Iis Inayati Rakhmat, Yudith Yunia Kusmala, Dewi Ratih Handayani, Henny Juliastuti, Eka Noneng Nawangsih, Arief Wibowo, Michael Anthonius Lim, Raymond Pranata
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(3): 777.     CrossRef
• Post-infection depressive, anxiety and post-traumatic stress symptoms: A prospective cohort study in patients with mild COVID-19
  Flavia Ismael, João C.S. Bizario, Tatiane Battagin, Beatriz Zaramella, Fabio E. Leal, Julio Torales, Antonio Ventriglio, Megan E. Marziali, Silvia S. Martins, João M. Castaldelli-Maia
  Progress in Neuro-Psychopharmacology and Biological Psychiatry.2021; 111: 110341.     CrossRef
• Managing diabetes in diabetic patients with COVID: where do we start from?
  Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
  Acta Diabetologica.2021; 58(11): 1441.     CrossRef
• Is diabetes mellitus a wrongdoer to COVID-19 severity?
  Sanjib Sarkar, Dibyendu Das, Sawlang Borsingh Wann, Jatin Kalita, Prasenjit Manna
  Diabetes Research and Clinical Practice.2021; 178: 108936.     CrossRef
• Dipeptidyl Peptidase 4 Inhibitor, an Update
  Ju Hee Lee
  The Journal of Korean Diabetes.2021; 22(2): 91.     CrossRef
• Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19
  Zhenmu Jin, Mo Zheng, Jichan Shi, Xinchun Ye, Fang Cheng, Que-Lu Chen, Jianping Huang, Xian-Gao Jiang
  Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
• Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
  Anna R. Kahkoska, Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Stürmer, Kajsa Kvist, John B. Buse, Tim Q. Duong
  Diabetes Care.2021; 44(7): 1564.     CrossRef
• The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus
  Wenxing Yang, Xuehong Sun, Jun Zhang, Kui Zhang
  Diabetes Research and Clinical Practice.2021; 178: 108977.     CrossRef
• Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
  Jordan Loader, Erik Lampa, Stefan Gustafsson, Thomas Cars, Johan Sundström
  Journal of the American Heart Association.2021;[Epub]     CrossRef
• Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus
  Ayça Elibol, Didem Eren, Macide Deniz Erdoğan, Merve Elmaağaç, Oguzhan Sıtkı Dizdar, İlhami Çelik, Ali İhsan Günal
  Primary Care Diabetes.2021; 15(5): 806.     CrossRef
• Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors
  Melina Farshbafnadi, Sara Kamali Zonouzi, Mohammadmahdi Sabahi, Mahsa Dolatshahi, Mohammad Hadi Aarabi
  Experimental Gerontology.2021; 154: 111507.     CrossRef
• Classical and Counter-Regulatory Renin–Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology
  Moudhi Almutlaq, Abir Abdullah Alamro, Fayhan Alroqi, Tlili Barhoumi
  CJC Open.2021; 3(8): 1060.     CrossRef
• Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
  Yin Li, Xue Yang, Peijing Yan, Tong Sun, Zhi Zeng, Sheyu Li
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
  Marina Treskova-Schwarzbach, Laura Haas, Sarah Reda, Antonia Pilic, Anna Borodova, Kasra Karimi, Judith Koch, Teresa Nygren, Stefan Scholz, Viktoria Schönfeld, Sabine Vygen-Bonnet, Ole Wichmann, Thomas Harder
  BMC Medicine.2021;[Epub]     CrossRef
• COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
  Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
  Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
• High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
  Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
  Endocrinology and Metabolism.2021; 36(4): 800.     CrossRef
• Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  Chengxia Kan, Yang Zhang, Fang Han, Qian Xu, Tongtong Ye, Ningning Hou, Xiaodong Sun
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
  E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
  Kardiologiia.2021; 61(9): 20.     CrossRef
• Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
  Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
  Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545.     CrossRef
• COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
  Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis
  Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
  SSRN Electronic Journal .2021;[Epub]     CrossRef
• Decision Trees: Predictions of Global Vulnerability to Coronavirus Outbreaks
  Moacir José da Silva
  SSRN Electronic Journal .2020;[Epub]     CrossRef
• The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis
  Liman Luo, Menglu Fu, Yuanyuan Li, Shuiqing Hu, Jinlan Luo, Zhihui Chen, Jing Yu, Wenhua Li, Ruolan Dong, Yan Yang, Ling Tu, Xizhen Xu
  Clinical Cardiology.2020; 43(12): 1478.     CrossRef
• The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
  Antonia Anna Lukito, Raymond Pranata, Joshua Henrina, Michael Anthonius Lim, Sherly Lawrensia, Ketut Suastika
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2177.     CrossRef
• Risk Factors on the Progression to Clinical Outcomes of COVID-19 Patients in South Korea: Using National Data
  Seon-Rye Kim, Seoul-Hee Nam, Yu-Rin Kim
  International Journal of Environmental Research and Public Health.2020; 17(23): 8847.     CrossRef
• Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea
  Ji Hong You, Sang Ah Lee, Sung-Youn Chun, Sun Ok Song, Byung-Wan Lee, Dae Jung Kim, Edward J. Boyko
  Endocrinology and Metabolism.2020; 35(4): 901.     CrossRef

Citations

Citations to this article as recorded by  

• Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  Jing Wang, Xin Li, Yang Li, Chen Lei
  BMC Endocrine Disorders.2024;[Epub]     CrossRef
• Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
  Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi
  Expert Opinion on Pharmacotherapy.2024; 25(7): 925.     CrossRef
• Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes
  Derun Taner Ertugrul, Erdal Kan, Cigdem Bahadir Tura, Haci Bayram Tugtekin, Hayati Ayakta, Mehmet Celebioglu, Ceren Yılmaz, Onur Utebay, Ilhan Yetkin, Eren Gurkan, Kerem Sezer, Ramazan Gen, Suleyman Ozcaylak, Yildiz Okuturlar, Mehmet Coskun, Nilgun Govec
  International Journal of Diabetes in Developing Countries.2022; 42(1): 147.     CrossRef

• SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

  
  André J Scheen
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2765.     CrossRef
• Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
  Eugene Han, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
  Journal of Clinical Medicine.2020; 9(1): 259.     CrossRef
• Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials
  Atsunori Kashiwagi, Marina V. Shestakova, Yuichiro Ito, Masahiro Noguchi, Wim Wilpshaar, Satoshi Yoshida, John P. H. Wilding
  Diabetes Therapy.2019; 10(6): 2201.     CrossRef
• Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes
  Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(2): 1679.     CrossRef
• Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation
  Hongmei Wang, Gaoqiong Yao, Xi Chen, Jing Ouyang, Jiadan Yang
  Diabetes Research and Clinical Practice.2019; 157: 107867.     CrossRef
• Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
  Eugene Han, Ari Kim, Sung Jae Lee, Je-Yon Kim, Jae Hyeon Kim, Woo Je Lee, Byung-Wan Lee
  Diabetes Therapy.2018; 9(4): 1689.     CrossRef
• A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
  Marina V. Shestakova, John P.H. Wilding, Wim Wilpshaar, Reiner Tretter, Valeria L. Orlova, Andrey F. Verbovoy
  Diabetes Research and Clinical Practice.2018; 146: 240.     CrossRef
• Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
  Kyung‐Ah Han, Suk Chon, Choon Hee Chung, Soo Lim, Kwan‐Woo Lee, SeiHyun Baik, Chang Hee Jung, Dong‐Sun Kim, Kyong Soo Park, Kun‐Ho Yoon, In‐Kyu Lee, Bong‐Soo Cha, Taishi Sakatani, Sumi Park, Moon‐Kyu Lee
  Diabetes, Obesity and Metabolism.2018; 20(10): 2408.     CrossRef
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
• Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
• Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
  Min Kyong Moon, Kyu Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 974.     CrossRef
• Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
  Min Kyong Moon, Kyu-Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
  Diabetes & Metabolism Journal.2017; 41(5): 357.     CrossRef